Quantcast

Industry news that matters to you.  Learn more

Caprion Proteomics Identifies Promising New Candidate Biomarkers to Predict Response to Hepatitis C Treatment

Caprion Proteomics announced today that it has identified promising candidate protein biomarker panels that appear to predict patient responsiveness to treatment for hepatitis C.

The study employed Caprion’s proprietary CellCarta mass spectrometry-based proteomics discovery platform to measure and compare the expression levels of thousands of proteins contained in blood samples collected from patients infected with the hepatitis C virus (HCV), in order to discover predictive biomarkers of sustained response to hepatitis C therapy.

Exagen Buys Cypress’ Diagnostics Business

Exagen Diagnostics Inc. acquired the medical diagnostics division of Cypress Bioscience Inc. in San Diego, Calif.